The Indonesian government has implemented mandatory halal certification to protect its predominantly Muslim population. To ensure halal standards, the government has issued several key regulations, including Law No. 33 of 2014 concerning Halal Product Assurance, Government Regulation No. 42 of 2024 concerning Implementation of Halal Product Assurance, and specifically for imported products, Decision of the Head of Halal Product Assurance Agency (BPJPH) No. 90 of 2023 concerning Procedures of Implementing Foreign Halal Certificate Registration. Compliance Deadlines The government has established statutory deadlines for products and services to obtain halal certification under Government Regulation No. 39 of 2021 concerning Implementation of Halal Product Assurance. The deadline for imported food, beverages, and slaughtering products and services to comply with halal certification was extended to October 17, 2026 (from October 17, 2024, originally) with the issuance of Government Regulation No. 42 of 2024. Other product categories have varying deadlines: October 17, 2026: Natural drugs, quasi-drugs, health supplements, cosmetics, chemical products, genetically engineered products, clothing and accessories, household supplies, prayer equipment, stationery, and class A medical devices October 17, 2029: Over-the-counter drugs and class B medical devices October 17, 2034: Prescription drugs (excluding psychotropics) and class C medical devices SHLN Registration for Imports To simplify the halal certification process for imported products, BPJPH offers a foreign halal certificate registration (Registrasi Sertifikat Halal Luar Negeri, or SHLN registration) pathway. This allows eligible imported products to obtain halal certification without filing the standard national halal certification procedure. Under the Halal Law, imported products are not required to apply for national halal certification if their halal certificate is issued by a foreign halal institution that has entered into a mutual recognition agreement (MRA) with BPJPH. Currently, 89 foreign halal institutions from countries (including the United States, South Korea, Thailand, and the United Kingdom) have entered into

With advancements in health technology, telemedicine has taken on a wider online presence in Thailand. Under the Medical Facility Act, licensed clinics and hospitals may now diagnose, prescribe, and issue electronic prescriptions during a video call, provided they maintain patient confidentiality and proper recordkeeping. As a complementary concept, a telepharmacy allows a pharmacist to verify prescriptions, counsel patients, and dispense medication from a remote site. Hospitals, clinic chains, and some retail pharmacy groups have adopted “drive-thru” or “locker” pick-up points where drugs are bagged only after a real-time video consultation with a registered pharmacist. The clear benefits of telehealth include shorter waiting times and broader access to specialists, which is in the public interest. Drug Distribution and Advertising in Thailand The online pharmacy ecosystem creates a legal bridge in that once a teleconsulting doctor issues an e-prescription, a licensed pharmacy can lawfully dispense and deliver the medicine prescribed to the patient’s door. Nonetheless, the critical compliance component remains the advertising of medicinal drugs. It is still not allowed to advertise prescription/pharmacy-dispensed drugs to the public in Thailand. Although Thailand’s Drug Act of 1967 was written more than half a century ago, it still governs the trading of every medicinal drug that makes its way to consumers in Thailand—whether bought at a pharmacy or delivered with a few taps on a smartphone. First and foremost, the pharmacy must hold a license to sell medicinal drugs as a retailer. It is also mandatory that arrangements be made for a pharmacist to be on duty during opening hours. Drugs are classified into three main categories: prescription drugs, pharmacy-dispensed drugs, and over-the-counter (OTC) drugs. The listing of OTC drugs with their prices via an online platform is allowed, as only OTC drugs may be advertised directly to the public. However, naming or showing

On June 6, 2025, the Superior People’s Court in Hanoi overturned a non-use cancellation decision by the Intellectual Property Office of Vietnam, a rare and impactful occurrence. In a ruling that may help clarify the enforcement of Vietnam’s IP Law, the court held that valid trademark use can be established through commercial arrangements where the brand owner maintains actual control over the use of the mark, and is not confined to relationships governed by a so-called “formal license agreement. Background: Cross-Border Use, Local Challenge A Singapore company owns a well-known brand of consumer products that has gained recognition across Southeast Asia. In recent years, the brand has been targeted by several unauthorized trademark filings in Vietnam. In one such instance, a local Vietnamese trading company—previously linked to the production and export of counterfeit goods to neighboring countries—filed a non-use cancellation against the Singapore company’s mark and sought to register it under its own name. If the cancellation had been upheld, it would have enabled a complete hijacking of the brand. The IP holder operates in Vietnam through a structured cross-border supply chain. Under an agreement between two related foreign entities, one of which managed regional operations, production orders were placed through a designated Vietnamese company. While the Vietnamese manufacturer was not a party to the agreement, its role in using the mark was recognized and governed by internal and commercial documentation. The Vietnamese manufacturer lawfully obtained the necessary permits, regulatory approvals, and customs clearances for producing the goods in Vietnam. These activities were supported by banking records and internal communications, evidencing active, continuous use of the mark in Vietnam. However, the IP Office concluded that this use did not meet the statutory criteria because the Vietnamese manufacturer did not have a direct license agreement with the brand owner, as

Liberal cannabis access in Thailand is officially over. On June 26, 2025, the Ministry of Public Health brought the inflorescence of cannabis back under tight control through its new Notification on Controlled Herbs (Cannabis) 2025 (“Notification 2025”). The message is that cannabis may stay in the marketplace, but only if strictly supervised under a cannabis prescription from a medical professional. Two main pillars now define compliance: (1) prescription requirements and mandatory reporting, and (2) Good Agricultural and Collection Practices (GACP). This article aims to summarize each essential element for the relevant parties. 1. Getting a Prescription: Digital Diagnosis vs. Real-World Paperwork? Dispensaries, even those with a license to sell cannabis, can no longer sell cannabis to walk-in customers who don’t have a valid prescription. Sales are lawful only when the buyer duly presents a cannabis prescription issued by one of seven recognized professional practitioners, including medical doctors, Thai traditional medicine doctors, applied Thai traditional medicine doctors, folk healers, Chinese medicine practitioners, pharmacists, or dentists. Notification 2025 does not mention teleconsultations or online prescriptions. Nonetheless, policymakers at this stage opine that an online chat or casual consultation, with the prescription sent via a social media platform or e-mail, would not comply with this latest regulation. In order to be eligible to issue cannabis prescriptions, medical doctors should be working in a clinic or hospital and should issue paper-based prescriptions. The official prescription form, called a PT 33, must be used. The prescriber has the discretion to indicate the cannabis strain (or product type), dosage, and intended duration of use, which cannot exceed 30 days per prescription. This ensures that the product matches the patient’s medical needs and aligns with professional treatment guidelines. In practice, each prescription will be valid for one-time use only and cannot be refilled; a new prescription